Table 2.

Prerequisites for peptide receptor radionuclide therapy

Histologically proven neuroendocrine tumor (immunohistochemistry)

High somatostatin receptor (SSTR) expression determined by immunohistochemistry or functional imaging of SSTR (using Tc-99m-labeled somatostatin analogs, or better with positron emission tomography/computed tomography using Ga-68-labeled somatostatin analogs)

Karnofsky/Lansky performance status > 60% or ECOG < 2

Tumor differentiation: well-differentiated, preferably G1 or G2

Proliferation rate (Ki67/mitotic index) of the tumor preferably ≤20%